Cargando…

Use of extracorporeal immunomodulation in a toddler with hemophagocytic lymphohistiocytosis and multisystem organ failure

INTRODUCTION: Hemophagocytic lymphohistiocytosis (HLH) is a dysregulated immune disorder in children, associated with Epstein–Barr virus (EBV) infection or malignancies. In severe forms, HLH presents with signs and symptoms of hyperinflammation that progress to life-threatening multiorgan failure. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Goldstein, Stuart L., Yessayan, Lenar T., Krallman, Kelli A., Collins, Michaela, Benoit, Stefanie, Westover, Angela, Humes, H. David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307428/
https://www.ncbi.nlm.nih.gov/pubmed/35869162
http://dx.doi.org/10.1007/s00467-022-05692-1
_version_ 1784752760792547328
author Goldstein, Stuart L.
Yessayan, Lenar T.
Krallman, Kelli A.
Collins, Michaela
Benoit, Stefanie
Westover, Angela
Humes, H. David
author_facet Goldstein, Stuart L.
Yessayan, Lenar T.
Krallman, Kelli A.
Collins, Michaela
Benoit, Stefanie
Westover, Angela
Humes, H. David
author_sort Goldstein, Stuart L.
collection PubMed
description INTRODUCTION: Hemophagocytic lymphohistiocytosis (HLH) is a dysregulated immune disorder in children, associated with Epstein–Barr virus (EBV) infection or malignancies. In severe forms, HLH presents with signs and symptoms of hyperinflammation that progress to life-threatening multiorgan failure. Intervention with an extracorporeal immunomodulatory treatment utilizing a selective cytopheretic device (SCD) could be beneficial. The SCD with regional citrate anticoagulation selectively binds the most highly activated circulating neutrophils and monocytes and deactivates them before release to the systemic circulation. Multiple clinical studies, including a multicenter study in children, demonstrate SCD therapy attenuates hyperinflammation, resolves ongoing tissue injury and allows progression to functional organ recovery. We report the first case of SCD therapy in a patient with HLH and multi-organ failure. CASE DIAGNOSIS/TREATMENT: A previously healthy 22-month-old toddler presented with fever, abdominal distension, organomegaly, pancytopenia, and signs of hyperinflammation. EBV PCR returned at > 25 million copies. The clinical and laboratory pictures were consistent with systemic EBV-positive T-cell lymphoma with symptoms secondary to HLH. The patient met inclusion criteria for an ongoing study of integration of the SCD with a continuous kidney replacement therapy (CKRT) as part of standard of care. The patient received CKRT-SCD for 4 days with normalization of serum markers of sepsis and inflammation. The patient underwent hematopoietic stem cell transplantation 52 days after presentation and has engrafted with normal kidney function 8 months later. CONCLUSIONS: SCD treatment resulted in improvement of poor tissue perfusion reflected by rapid decline in serum lactate levels, lessened systemic capillary leak with discontinuation of vasoactive agents, and repair and recovery of lung and kidney function with extubation and removal of hemodialysis support.
format Online
Article
Text
id pubmed-9307428
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-93074282022-07-25 Use of extracorporeal immunomodulation in a toddler with hemophagocytic lymphohistiocytosis and multisystem organ failure Goldstein, Stuart L. Yessayan, Lenar T. Krallman, Kelli A. Collins, Michaela Benoit, Stefanie Westover, Angela Humes, H. David Pediatr Nephrol Brief Report INTRODUCTION: Hemophagocytic lymphohistiocytosis (HLH) is a dysregulated immune disorder in children, associated with Epstein–Barr virus (EBV) infection or malignancies. In severe forms, HLH presents with signs and symptoms of hyperinflammation that progress to life-threatening multiorgan failure. Intervention with an extracorporeal immunomodulatory treatment utilizing a selective cytopheretic device (SCD) could be beneficial. The SCD with regional citrate anticoagulation selectively binds the most highly activated circulating neutrophils and monocytes and deactivates them before release to the systemic circulation. Multiple clinical studies, including a multicenter study in children, demonstrate SCD therapy attenuates hyperinflammation, resolves ongoing tissue injury and allows progression to functional organ recovery. We report the first case of SCD therapy in a patient with HLH and multi-organ failure. CASE DIAGNOSIS/TREATMENT: A previously healthy 22-month-old toddler presented with fever, abdominal distension, organomegaly, pancytopenia, and signs of hyperinflammation. EBV PCR returned at > 25 million copies. The clinical and laboratory pictures were consistent with systemic EBV-positive T-cell lymphoma with symptoms secondary to HLH. The patient met inclusion criteria for an ongoing study of integration of the SCD with a continuous kidney replacement therapy (CKRT) as part of standard of care. The patient received CKRT-SCD for 4 days with normalization of serum markers of sepsis and inflammation. The patient underwent hematopoietic stem cell transplantation 52 days after presentation and has engrafted with normal kidney function 8 months later. CONCLUSIONS: SCD treatment resulted in improvement of poor tissue perfusion reflected by rapid decline in serum lactate levels, lessened systemic capillary leak with discontinuation of vasoactive agents, and repair and recovery of lung and kidney function with extubation and removal of hemodialysis support. Springer Berlin Heidelberg 2022-07-23 2023 /pmc/articles/PMC9307428/ /pubmed/35869162 http://dx.doi.org/10.1007/s00467-022-05692-1 Text en © The Author(s), under exclusive licence to International Pediatric Nephrology Association 2022 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Brief Report
Goldstein, Stuart L.
Yessayan, Lenar T.
Krallman, Kelli A.
Collins, Michaela
Benoit, Stefanie
Westover, Angela
Humes, H. David
Use of extracorporeal immunomodulation in a toddler with hemophagocytic lymphohistiocytosis and multisystem organ failure
title Use of extracorporeal immunomodulation in a toddler with hemophagocytic lymphohistiocytosis and multisystem organ failure
title_full Use of extracorporeal immunomodulation in a toddler with hemophagocytic lymphohistiocytosis and multisystem organ failure
title_fullStr Use of extracorporeal immunomodulation in a toddler with hemophagocytic lymphohistiocytosis and multisystem organ failure
title_full_unstemmed Use of extracorporeal immunomodulation in a toddler with hemophagocytic lymphohistiocytosis and multisystem organ failure
title_short Use of extracorporeal immunomodulation in a toddler with hemophagocytic lymphohistiocytosis and multisystem organ failure
title_sort use of extracorporeal immunomodulation in a toddler with hemophagocytic lymphohistiocytosis and multisystem organ failure
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307428/
https://www.ncbi.nlm.nih.gov/pubmed/35869162
http://dx.doi.org/10.1007/s00467-022-05692-1
work_keys_str_mv AT goldsteinstuartl useofextracorporealimmunomodulationinatoddlerwithhemophagocyticlymphohistiocytosisandmultisystemorganfailure
AT yessayanlenart useofextracorporealimmunomodulationinatoddlerwithhemophagocyticlymphohistiocytosisandmultisystemorganfailure
AT krallmankellia useofextracorporealimmunomodulationinatoddlerwithhemophagocyticlymphohistiocytosisandmultisystemorganfailure
AT collinsmichaela useofextracorporealimmunomodulationinatoddlerwithhemophagocyticlymphohistiocytosisandmultisystemorganfailure
AT benoitstefanie useofextracorporealimmunomodulationinatoddlerwithhemophagocyticlymphohistiocytosisandmultisystemorganfailure
AT westoverangela useofextracorporealimmunomodulationinatoddlerwithhemophagocyticlymphohistiocytosisandmultisystemorganfailure
AT humeshdavid useofextracorporealimmunomodulationinatoddlerwithhemophagocyticlymphohistiocytosisandmultisystemorganfailure